NDA 220837 · Apotex
Evdi
Trabectedin · Intravenous · Alkylating Drug
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
May 1, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
89
18 Phase 3, 12 recruiting
FAERS reports
1,205
1,178 serious, 261 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 29, 2026.
EVDI is indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14) ] . EVDI is an alkylating drug indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen ( 1 )
Mechanism: Trabectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. Adduct formation triggers a cascade of events that can affect the subsequent activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- EVDI · TRABECTEDIN 1MG/20ML (0.05MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Trabectedin" as an intervention, any sponsor and status, largest first.
- An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian CancerPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00113607 · 672 participants · Start Apr 2005 · Primary completion Nov 2010
Drug: Trabectedin; DOXIL and 1 more · For: Ovarian Cancer
Sites: Mobile, Alabama; Tucson, Arizona; Los Angeles, California · 111 sites in all
- INOVATYON STUDY -International, Randomized Study in Patients With Ovarian CancerPivotal-lookingCompleted
Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
NCT01379989 · 617 participants · Start Jun 2011 · Primary completion Dec 17, 2020
Drug: Carboplatin; Pegylated Lipoxomal Doxorubicin (PLD) and 1 more · For: Ovarian Cancer
Sites: Graz, Austria; Innsbruck, Austria; Vienna, Austria · 132 sites in all
- A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01846611 · 581 participants · Start Oct 16, 2013 · Primary completion Jan 18, 2018
Drug: Trabectedin; DOXIL and 2 more · For: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 138 sites in all
- A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or LeiomyosarcomaPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01343277 · 579 participants · Start Jun 2011 · Primary completion Jan 2015
Drug: Trabectedin; Dacarbazine · For: Advanced Liposarcoma or Leiomyosarcoma
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 88 sites in all
- Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant ChemotherapyPivotal-lookingCompleted
Italian Sarcoma GroupResearch network
NCT01710176 · 550 participants · Start Jun 1, 2011 · Primary completion Jun 30, 2024
Drug: epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3); gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8) and 4 more · For: Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults
Sites: Candiolo, Italy; Aviano (PN), Italy; Bologna, Italy · 15 sites in all
- A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)Pivotal-lookingRecruiting
Intensity Therapeutics, Inc.Industry
NCT06263231 · 333 participants (planned) · Start Jun 28, 2024 · Primary completion Dec 2027
Drug: INT230-6; Eribulin and 2 more · For: Sarcoma,Soft Tissue
Sites: Phoenix, Arizona; Los Angeles, California; Santa Monica, California · 20 sites in all
- A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced CancerPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00060944 · 271 participants · Start May 2003 · Primary completion May 2008
Drug: Yondelis; Yondelis and 2 more · For: Liposarcoma; Leiomyosarcoma
Sites: Los Angeles, California; Aurora, Colorado; Coeur d'Alene, Idaho · 39 sites in all
- SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue SarcomaRecruiting
Sarcoma Oncology Research Center, LLCAcademic, hospital or other
NCT03138161 · 250 participants (planned) · Start Apr 13, 2017 · Primary completion Dec 31, 2030
Drug: Trabectedin; Ipilimumab and 1 more · For: Advanced Soft Tissue Sarcoma; Metastatic Soft Tissue Sarcoma
Sites: Santa Monica, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neutropenia159
- anaemia133
- thrombocytopenia132
- disease progression118
- nausea109
- febrile neutropenia107
- drug ineffective93
- vomiting92
- off label use86
- asthenia72
- fatigue66
- pancytopenia64
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 11 |
| 2011 | 32 |
| 2012 | 19 |
| 2013 | 12 |
| 2014 | 14 |
| 2015 | 48 |
| 2016 | 101 |
| 2017 | 91 |
| 2018 | 121 |
| 2019 | 127 |
| 2020 | 94 |
| 2021 | 71 |
| 2022 | 88 |
| 2023 | 100 |
| 2024 | 107 |
| 2025 | 77 |
| 2026 | 83 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.
Pautier P, Italiano A, Piperno-Neumann S, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, et al. · Lancet Oncol 2022 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD, von Mehren M, Jones RL, et al. · J Clin Oncol 2016 · Clinical Trial, Phase III, Multicenter Study
- Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial.
Grohar PJ, Heise R, Wedekind MF, et al. · Nat Med 2026 · Clinical Trial, Phase II, Clinical Trial, Phase I
- TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group.
Fabbroni C, Grignani G, Vincenzi B, et al. · ESMO Open 2024 · Clinical Trial, Phase II, Multicenter Study
- Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).
Gronchi A, Palmerini E, Quagliuolo V, et al. · J Clin Oncol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Apotex
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.